Maternal visfatin concentration in normal pregnancy.

Area of Science:

• Endocrinology
• Metabolic research
• Pregnancy physiology

Background:

• Adipose tissue functions as an endocrine organ producing adipokines.
• Visfatin, a novel adipokine, is linked to insulin resistance in obesity and Type-2 diabetes mellitus.
• Understanding visfatin's role in pregnancy is crucial for metabolic health during gestation.

Purpose of the Study:

• To investigate changes in maternal plasma visfatin concentration during advancing gestation.
• To examine if maternal weight status (normal vs. overweight/obese) influences these visfatin changes.
• To explore the relationship between visfatin, gestational age, and maternal weight.

Main Methods:

• Cross-sectional study design involving pregnant women across different gestational age groups.
• Maternal plasma visfatin concentrations measured using ELISA.
• Statistical analysis performed using non-parametric tests to compare groups.

Main Results:

• Maternal plasma visfatin peaked between 19-26 weeks of gestation, significantly higher than 11-14 and 27-34 weeks.
• In normal-weight women, visfatin levels followed a similar peak pattern.
• Overweight/obese women exhibited similar visfatin concentrations across gestational age groups, differing from normal-weight women.

Conclusions:

• Maternal plasma visfatin concentration exhibits a distinct pattern, peaking in early-mid gestation (19-26 weeks) and declining thereafter.
• The dynamic changes in circulating visfatin concentrations during pregnancy differ between normal-weight and overweight/obese women.
• These findings highlight potential gestational metabolic alterations influenced by visfatin and maternal weight.